Trump proposes up to 200% tariff on imported generic drugs (phased); Indian pharma falls, takes wait-and-watch stance
23 Jul, 04:24 IST · Plays out over months · 7 sources
Key facts
What the reporting establishes, before any reading of it.
- Trump proposes tariffs on imported generic drugs PHASED: 0% for two years from Aug 1 2026, 100% from Aug 1 2028, 200% from Aug 1 2029 — designed to push manufacturing to the US.
- Nifty Pharma fell ~1.3%, led by Lupin and Piramal Pharma; India supplies a large share of US generics (~$30bn export market).
- Indian pharma calls the plan 'not practical' and takes a wait-and-watch approach; Dr Reddy's says it 'won't do anything special' and warns US consumers will pay higher prices.
How the news spreads
Step by step — from the first companies it hits to whole sectors.
Who it hits first
- US-facing Indian generic exporters (DRREDDY, AUROPHARMA, LUPIN, ZYDUSLIFE, GLAND) face a long-dated tariff threat with zero near-term cost
- Sentiment hit today; Nifty Pharma -1.3%
Who may gain
- Domestic-focused pharma/hospitals (APOLLOHOSP, MANKIND, ABBOTINDIA) relatively insulated
- US-based generic manufacturers long-term if reshoring occurs
Along the supply chain
Downstream
US pharmacies/PBMs and patients would bear higher generic costs if the tariff ever takes effect, which is the political friction that makes near-term enactment on essential generics unlikely.
Upstream
Indian API/intermediate suppliers to these formulators see no near-term change; a post-2028 US reshoring push could shift some API demand but also open US-site sourcing.
Where demand moves
Business
No near-term demand change (0% tariff for 2 years). If enacted post-2028, US buyers of Indian generics would face higher landed cost, incentivising reshoring or supplier switching; specialty/injectable makers are harder to displace.
Capital
Near-term risk-off rotation within pharma from high-US-generics names toward domestic-facing pharma and hospitals; the muted, recoverable Sept-2025 precedent limits sustained outflows.
How it spreads across sectors
Healthcare
Domestic hospitals/branded pharma relatively insulated, mild defensive bid
Pharma
US-generic exporters sentiment-negative near-term, neutral medium-term given phasing
When it plays out
Immediate
Sentiment-driven dip in US-exposed generic exporters (Nifty Pharma -1.3%); no earnings impact
Medium term
Neutral through 2026-27 (0% tariff); structural risk only from Aug-2028 (100%) / Aug-2029 (200%) if unmodified — 2 years to reshore or requalify supply
Short term
Wait-and-watch; watch for exemptions/clarifications on essential generics and any reshoring announcements